PILL.CN - Canntab Therapeutics Limited

Canadian Sec - Canadian Sec Delayed Price. Currency in CAD

Canntab Therapeutics Limited

223 Riviera Drive
Markham, ON L3R 5J6

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Jeffrey W. RenwickCo-Founder, CEO & Director20kN/A1968
Mr. Richard C. GoldsteinCo-Founder, CFO & Director20kN/A1961
Mr. Barry M. PolisukChairman & Corp. Sec.N/AN/A1960
Mr. Robert LeflerDirector of OperationsN/AN/AN/A
Mr. Joshi LaxminarayanChief Scientific OfficerN/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


Canntab Therapeutics Limited researches and develops advanced pharmaceutical grade formulations of cannabinoids and terpenes in Canada. It offers sustained release, immediate release, modified release, flash melt, and bi-layered tablets for treating sleep disorders, posttraumatic stress disorder, social anxiety, addiction, arthritis, general pain, pain management and appetite loss associated with cancer treatments, and addiction treatment therapy of opioids and other painkillers. Canntab Therapeutics Limited is headquartered in Markham, Canada.

Corporate Governance

Canntab Therapeutics Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.